TET signs rights to gene expression patents

Licensing

TET Systems Holding (TSH), a privately-held, German biotech company based in Heidelberg, has entered into licensing agreement with the Academic Medical Centre (AMC) in Amsterdam.

Scientists at the AMC have developed a novel series of reverse transactivators with improved properties, for controlling gene expression in higher organisms. Under the terms of the agreement, eight patent applications covering these new transactivators have been assigned to TSH for commercialisation.

“We are excited to enter into this partnership with TET Systems Holding as it opens the way to broad use of our improved transactivators in the scientific community, but also in the biotech and pharma industry,” said Joris Heus of AMC’s Technology Transfer Office.